Optogenetics Market Thrives Amid Rising Neurological Disorders

The optogenetics market, driven by advancements in neuroscience and rising neurological disorders, is projected to grow from USD 580.7 million in 2023 to USD 772.7 million by 2030.
 
NEW YORK - July 23, 2024 - PRLog -- The global optogenetics market achieved USD 580.7 million in revenue in 2023 and is expected to grow at a 4.4% CAGR, reaching USD 772.7 million by 2030. This growth is driven by the expanding use of optogenetics in neuroscience as a potential analytical tool, supported by technological advancements and the increased use of multimodal imaging techniques.

The rise in neurological disorders, due to infections, genetic factors, brain and spinal cord injuries, and congenital anomalies, is also fueling market growth. The global incidence of neurological conditions has increased over time. The growing prevalence of these chronic illnesses, along with the pressures of modern life and financial stress, is anticipated to drive demand for the diagnosis and treatment of psychiatric disorders, where optogenetics is used to monitor behavior.

Currently, around 20% of the world's adolescents and children suffer from psychiatric issues, a number that is steadily rising, with suicide being the second-leading cause of death among 15–29-year-olds. In post-conflict situations, one in five people experience mental illness. Additionally, 6% of the population has experienced a neurological disorder at some point.

Browse detailed report analysis on Optogenetics Market Share, Development and Forecast Report, 2030 (https://www.psmarketresearch.com/market-analysis/optogene...)

In the light equipment market, the laser category led with approximately 60% of the revenue in 2023, a trend expected to continue throughout the decade. Laser technology is widely used in biotechnology and neuroscience to deliver precise optical laser radiation to specific areas of interest. Technological advancements have led to the creation of compact, portable laser sources designed for use in clinical and diagnostic laboratories, offering user-friendly designs, long operational lifespans exceeding 10,000 hours, durability, and consistent performance.

In 2023, the channelrhodopsin category was the leading actuator segment, a trend projected to continue. Channelrhodopsins enable rapid neuron depolarization when exposed to light by directly stimulating ion channels. Blue light excites channelrhodopsins, allowing non-specific cation entry into cells. This first widely recognized optogenetic tool is a cation channel activated by blue light, showing high conductance at physiological pH and integrating well into the membrane.

North America held the largest market share in 2023, with about 55% of the total value, a dominance expected to persist throughout the forecast period. The U.S. contributes significantly to this regional market due to the increasing prevalence of severe behavioral conditions, such as Parkinson's disease and schizophrenia.

Contact
Vijay Kumar
***@psmarketresearch.com
End
Source: » Follow
Email:***@psmarketresearch.com
Posted By:***@psmarketresearch.com Email Verified
Tags:Optogenetics Market Size
Industry:Business
Location:New York City - New York - United States
Subject:Reports
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse



Like PRLog?
9K2K1K
Click to Share